Treatments

REGEN-COV Phase 3 Trial Improves Survival in Patients Hospitalized with Severe COVID-19

June 17, 2021

A Phase 3 RECOVERY trial in the UK found that Regeneron’s REGEN-COV antibody treatment reduced the risk of death by 20% in patients who had not mounted their own immune response against COVID-19. In addition, among patients without their own immune response, the median duration of hospital stay was 4 days shorter in the REGEN-COV group, and there was a greater proportion of patients discharged by 28 days. Research has also shown that the treatment remains effective against the main variants of COVID-19 in the United States. 

Read More »

Treating MIS-C with Phase 3 Celiac Drug

June 15, 2021

Even after a COVID-19 infection has passed, SARS-CoV-2 particles may linger in the gut and make their way into the bloodstream. This often triggers a cytokine storm and hyper-inflammatory response (MIS-C) within multiple areas of the body. These include the heart, lungs, kidneys, brain, and GI organs. 

Read More »

Targeted COVID Therapy: What Can we Learn From Autoimmune Kidney Diseases?

June 10, 2021

A study was recently published on the ability of antiphospholipid antibodies (aPLs) to bind to the “EPCR-LBPA” complex. Antiphospholipid antibodies are autoantibodies that target and attack phospholipid-binding proteins. This, researchers found, initiates a self-amplifying signaling loop related to the innate immune complement and coagulation pathways. 

Read More »

NIH Funds Clinical Trial For New COVID-19 Antibody Therapy

April 19, 2021

The NIH is funding a Phase 2 clinical trial testing a monoclonal antibody for COVID-19 patients hospitalized with respiratory disease and low blood oxygen count. The FDA has previously issued emergency use authorization for COVID-19 antibody therapies by Eli Lilly and Regeneron. 

Read More »
1 … 6 7 8 9

Browse By Topic